Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M. Pfaller MA, et al. Among authors: shortridge d. J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19. J Glob Antimicrob Resist. 2017. PMID: 28735046
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).
Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK. Pfaller MA, et al. Among authors: shortridge d. Braz J Infect Dis. 2017 Nov-Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21. Braz J Infect Dis. 2017. PMID: 28941394 Free PMC article.
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Pfaller MA, et al. Among authors: shortridge d. Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6. Int J Antimicrob Agents. 2018. PMID: 28993143
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Shortridge D, et al. Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17. Microb Drug Resist. 2018. PMID: 29039729
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Castanheira M, et al. Among authors: shortridge d. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar. Antimicrob Agents Chemother. 2018. PMID: 29263073 Free PMC article.
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program.
Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Shortridge D, et al. Diagn Microbiol Infect Dis. 2018 Oct;92(2):158-163. doi: 10.1016/j.diagmicrobio.2018.05.011. Epub 2018 May 18. Diagn Microbiol Infect Dis. 2018. PMID: 29891184
80 results